Synacthen 0
Sponsors
Mineralys Therapeutics Inc.
Conditions
HypertensionUncontrolled and Resistant Hypertension
Phase 3
MLS-101-301: A Randomized, Double-Blind, Placebo Controlled, Parallel Arm, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Lorundrostat in Subjects with Uncontrolled and Resistant Hypertension
CompletedCTIS2023-506425-12-00
Start: 2024-04-17End: 2025-01-16Target: 420Updated: 2025-01-24
MLS-101-901: An Open-Label Extension Study to Assess the Long-Term Safety, Efficacy, and Tolerability of Lorundrostat in Subjects with Hypertension
Active, not recruitingCTIS2023-508670-28-00
Start: 2024-08-26Target: 370Updated: 2025-12-19